{
  "trial_id": "NCT01660997",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Histologically or cytologically confirmed Smoldering Multiple Myeloma",
      "label": "met",
      "evidence": "positive anti-AChR antibody test, single fiber electromyography (SFEMG) was positive"
    },
    {
      "criterion": "Serum M-protein greater than or equal to 3 g/dl and/or bone marrow plasma cells greater than or equal to 10 %",
      "label": "met",
      "evidence": "Hgb: 11 g/dl, WBC: 8000 /mm3"
    },
    {
      "criterion": "Absence of anemia: Hemoglobin >10 g/dl",
      "label": "met",
      "evidence": "Hgb: 11 g/dl"
    },
    {
      "criterion": "Absence of renal failure: calculated creatinine clearance (according to MDRD) > 80 ml/min",
      "label": "met",
      "evidence": "Creatinine: 0.5 mg/dl"
    },
    {
      "criterion": "Age >18 years.",
      "label": "met",
      "evidence": "16-year-old girl"
    }
  ],
  "exclusion": [
    {
      "criterion": "Patients who are receiving any other investigational agents not included in this trial, within 21 days of the start of this trial and throughout the duration of this trial.",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "Prior therapy for SMM with a proteasome inhibitor.",
      "label": "unknown",
      "evidence": ""
    }
  ],
  "notes": "16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities.",
  "_meta": {
    "topic_id": "72",
    "trial_id": "NCT01660997",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}